Pediatr. praxi. 2020;21(5):364-368 | DOI: 10.36290/ped.2020.075

Kawasaki shock syndrome

prof. MUDr. Zdeněk Doležel, CSc.1, MUDr. Marie Macků1, MUDr. Jana Fráňová1, MUDr. Marcel Schüller, Ph.D.1, MUDr. Lukáš Homola, Ph.D.2, MUDr. Pavel Vít3
1 Pediatrická klinika LF MU a FN, Brno
2 Klinika dětských infekčních nemocí LF MU a FN, Brno
3 Oddělení dětské kardiologie Pediatrické kliniky LF MU a FN, Brno

Kawasaki disease (KD) was described more than 50 years ago and is still rare in our country. Etiopathogenesis KD has not been elucidated yet and similar findings of auxilliary examinations are missing. KD diagnosis still depends on the sequence of clinical signs that allow the determination of the classical variant of KD, but also the incomplete variant. Occasionally, it has been reported that some KD patients might present hemodynamic instability with severe shock symptoms. Herein we describe our experience with this serious course of KD.

Keywords: Kawasaki shock syndrome, heart failure, hypotension, immunoglobulins, corticosteroids.

Published: October 16, 2020  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Doležel Z, Macků M, Fráňová J, Schüller M, Homola L, Vít P. Kawasaki shock syndrome. Pediatr. praxi. 2020;21(5):364-368. doi: 10.36290/ped.2020.075.
Download citation

References

  1. Burns JC, Kushner HI, Bastian JF et al. Kawasaki disease: a brief history. Pediatrics 2000; 106: e27. Go to original source... Go to PubMed...
  2. Nagata S. Causes of Kawasaki disease - from past to present. Front. Pediatr. 2019; 7: 18. Go to original source... Go to PubMed...
  3. Kanegaye JT, Wilder MS, Molkara D et al. Recognition of a Kawasaki disease shock syndrome. Pediatrics 2009, 123(5); e783-e789. Go to original source... Go to PubMed...
  4. Ma L, Zhang YY, Yu HG. Clinical manifestations of Kawasaki disease shock syndrome. Clin Pediatr (Phila) 2018; 57(4): 428-435. Go to original source... Go to PubMed...
  5. Lin YJ, Cheng MC, Lo MH, Chien SJ. Early differentiation of Kawasaki disease shock syndrome and toxic shock syndrome in a pediatric intensive care unit. Pediatr Infect Dis J 2015; 34(11): 1163-1167. Go to original source... Go to PubMed...
  6. Taddio A, Dei Rossi E, Monasta L et al. Describing Kawasaki shock syndrome: results from a retrospective study and literature review. Clin Rheumatol 2017; 36(1): 223-228. Go to original source... Go to PubMed...
  7. Li Y, Zheng Q, Zou L et al. Kawasaki disease shock syndrome: clinical characteristics and possible use of IL-6, IL-10 and IFN‑γ as biomarkers for early recognition. Pediatric Rheumatology 2019; 17: 1. Go to original source... Go to PubMed...
  8. Lin KH, Chang SS, Yu CW et al. Usefulness of natriuretic peptide for the diagnosis of Kawasaki disease: a systematic review and meta‑analysis. BMJ Open 2015; 5: e006703. Go to original source... Go to PubMed...
  9. Cakan M, Gemici H, Aktay‑Ayaz N et al. Kawasaki disease shock syndrome: a rare and severe complication of Kawasaki disease. Turk J Pediatr 2016; 58: 415-418. Go to original source... Go to PubMed...
  10. De Rosa G, Andreozzi L, Piastra M et al. Acute myocarditis as a revealing clue of complete Kawasaki disease. Rheumatol 2018; 70(2): 115-116. Go to original source... Go to PubMed...
  11. Qiu H, Li C, He Y et al. Association between left ventricular ejection fraction and Kawasaki disease shock syndrome. Cardiol Young 2019; 29(2): 178-184. Go to original source... Go to PubMed...
  12. Falcini F, Capannini, Rigante D. Kawasaki syndrome: an intriguing disease with numerous unsolved dilemmas. Pediatric Rheumatology 2011; 9: 17. Go to original source... Go to PubMed...
  13. Brisse E, Wouters CH, Matthys P. Advances in the pathogenesis of primary and secondary haemophagocytic lymphohistiocytosis: differences and similarities. Br J Haematol 2016; 174: 203-217. Go to original source... Go to PubMed...
  14. Chen KYH, Messina N, Germano S et al. Innate immune responses following Kawasaki disease and toxic shock syndrome. PLoS ONe 2018; 13(2): e019830. Go to original source...
  15. Yozgat Y, Uzuner S, Demir AD et al. A 13-year‑old boy who has Kawasaki disease shock syndrome presents with parotitis. Pediatr intensive care 2020; 9(1): 60-63. Go to original source... Go to PubMed...
  16. Gamez GLB, Moribe QI, Cisneros CM et al. Kawasaki disease shock syndrome: unique and severe subtype of Kawasaki disease. Pediatr Int 2018; 60: 781-790. Go to original source... Go to PubMed...
  17. Suga K, Inoue M, Ono A et al. Early combined treatment with steroid and immunoglobulin is effective for serious Kawasaki disease complicated by myocarditis and encephalopathy. J Med Invest 2016; 63: 140-143. Go to original source... Go to PubMed...
  18. Sato T, Somura J, Maruo Y. Steroid pulse therapy for Kawasaki disease complicated with myocarditis. Indian Pediatrics 2016; 53: 1015-1016. Go to original source... Go to PubMed...
  19. Marchesi A, de Jacobis IT, Riganate D et al. Kawasaki disease: guidelines of Italian society of pediatrics, part II - treatment of resistant forms and cardiovascular complications, follow‑up, lifestyle and prevention of cardiovascular risks. Italian Journal of Pediatrics 2018; 44: 103. Go to original source... Go to PubMed...
  20. Abe Y, Ayuasawa M, Kawamura K et al. A combination therapy for Kawasaki disease with severe complications: a case report. Open Med 2020; 15: 8-13. Go to original source... Go to PubMed...
  21. Newburger JW, Takahashi M, Burns JC. Kawasaki disease. J Am Coll Cardiol 2016; 67: 1738-1749. Go to original source... Go to PubMed...
  22. Dietz SM, vanStijn D, Burgner D et al. Dissecting Kawasaki disease: a state‑of‑the‑art review. Eur J Pediatr 2017; 176(8): 995-1009. Go to original source... Go to PubMed...
  23. Dionne A, Dahdah N. Myocarditis and Kawasaki disease. Int J Rheum Dis 2018; 21(1): 45-49. Go to original source... Go to PubMed...
  24. Moussa T, Wagner‑Wiener L. Kawasaki disease: beynod IVIG and aspirin. Pediatr Ann 2019; 48(10): e400-e405. Go to original source... Go to PubMed...
  25. Soni PR, Noval Rivas M, Arditi M. Comprehensive update on Kawasaki disease vasculitis and myocarditis. Curr Rheumatol Rep 2020; 22(2): 6. Go to original source... Go to PubMed...




Pediatrics for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.